Several lines of evidence indicate that b-catenin acquires oncogenic activity when its intracellular concentration increases as a result of either mutation in the b-catenin gene itself or inactivation of the adenomatous polyposis coli (APC) gene. In an attempt to elucidate the molecular mechanisms underlying hepatocellular carcinogenesis, we have studied the frequency of b-catenin gene alterations in exon 3, a region known to represent a mutation hot spot, and its inappropriate protein expression by immunohistochemistry in 73 hepatocellular carcinomas (HCCs). The results were correlated with dierent clinical and pathological data, particularly with the presence or not of an associated cirrhosis. Fourteen (19%) HCCs showed b-catenin gene alterations with missense mutations in nine cases and interstitial deletions in ®ve cases. These genetic alterations were present in both cirrhotic and non-cirrhotic groups. By contrast, we did not ®nd any b-catenin gene alterations in the nine ®bromellar carcinomas we examined. Nuclear accumulation of the protein was observed in 18 of them (25%). Remarkably, these included ten of the 14 tumors harboring somatic mutations in the b-catenin gene (P50.001). Our results indicate that accumulation of b-catenin resulting from genetic mutations is a frequent event in non-®brolamellar type hepatocellular carcinoma. The close association between increased b-catenin protein stability and mutation indicates that immunohistochemistry may be a powerful method for the detection of the mutated protein in future clinical practice.
Introduction
In Western countries and in Japan, nearly 90% of hepatocellular carcinomas (HCCs) arise in a cirrhotic liver (Okuda et al., 1989; Trevisani et al., 1995) . Chronic infections by hepatitis B and C viruses as well as cirrhosis accompanying heavy alcohol intake represent the major risk factors of HCC. Like in other tumors, activation of oncogenes (c-myc, cyclin D1) and loss of tumor suppressor gene functions (p53 and Rb) have been reported in the development of HCC (Murakami et al., 1991; Laurent-Puig et al., 1992; Zhang et al., 1993 Zhang et al., , 1994 . However, in Western countries, these genetic alterations are far from being consistently implicated. Loss of heterozygosity at chromosomes 8p, 4q, 6q, 13q, 1p and 16p have also been identi®ed in a substantial proportion of HCC suggesting that a large number of genes are potentially involved in multistep liver carcinogenesis (Nagai et al., 1997; Boige et al., 1997; Marchio et al., 1997) . On the other hand, in the Western world, about 10% of HCC occur in a liver parenchyma which shows neither cirrhosis nor extensive ®brosis. Except for rare cases of chronic hepatitis B virus infection, no etiology is usually found. In addition, patients with HCC arising in a non-cirrhotic liver are usually younger than those with underlying cirrhosis. These clinical and pathological dierences between tumors occurring in non-and cirrhotic livers suggest distinct molecular mechanisms of oncogenesis.
b-catenin was ®rst isolated as an essential component of the E-cadherin-mediated cell ± cell adhesion system, which plays key roles in morphogenesis and maintenance of the normal tissue architecture (Aberle et al., 1996; Hirohashi, 1998) . It has been shown that the full adhesive function of E-cadherin is expressed only when its speci®c domain is bound to three distinct cytoplasmic proteins, a-, b-, and g-catenins. In addition to its function as a cell adhesion component, b-catenin is now widely recognized as an essential target for signal transduction pathways mediated by Wnt proteins (Molenaar et al., 1996; Behrens et al., 1996) . Regulation of the level of free cytoplasmic b-catenin is, at least in part, through the opposing actions of the adenomatous polyposis coli (APC) suppressor gene and the Wnt-1 proto-oncogene (Willert and Nusse, 1998) . The latter stabilizes b-catenin leading to its accumulation in the cytoplasm and its passage into the nucleus where it binds members of the Tcf-Lef family of transcription factors, activating gene transcription (Willert and Nusse, 1998; He et al., 1998) . By contrast, the interaction between wild-type APC and b-catenin is responsible for the down-regulation of the intracellular b-catenin level. APC cooperates with the glycogen synthase kinase-3b (GSK-3b) to regulate bcatenin via phosphorylation of serine and threonine residues, all of which are encoded by exon 3 of the bcatenin gene. In colorectal cancer and in melanoma cell lines, it has been demonstrated that b-catenin acquires oncogenic activity when it is mutated or when it is upregulated as a result of inactivation of APC (Rubinfeld et al., 1997; Morin et al., 1997) . Similar activating mutations of the b-catenin gene were recently reported *Correspondence: B Terris 5 The ®rst two authors contributed equally to this workin 18 ± 26% of human HCCs De la Coste et al., 1998) . It is however still unknown whether the observed mutations are correlated with stabilization of the b-catenin protein in the liver tumors and whether these alterations are related with etiology or histology. In the present study, we have analysed 73 HCCs for b-catenin gene alterations and for b-catenin protein accumulation and the ®ndings were correlated with clinical parameters.
Results

Immunohistochemistry
In non-tumorous livers, hepatocytes showed a moderate membranous staining for b-catenin (Figure 1a , NT). Neither cytoplasmic nor nuclear expression could be observed in these samples. Strong membranous expression of b-catenin was recognized in the intrahepatic bile ducts (Hering canals and proliferating ductules) (arrow in Figure 1a ). The great majority of the tumors (65 cases) showed a preserved uniform staining of the membrane with an intensity comparable to that of the adjacent non-tumorous liver (Figure 1b) . By contrast, eight HCCs showed a reduced membranous staining, three and two of them were of ®brolamellar and undierentiated types respectively (data not shown).
Eighteen (25%) HCCs showed a signi®cant proportion of cells with a strong b-catenin staining in the nucleus ( Figure 1a , T and Figure 1c) . A moderate cytoplasmic expression was generally associated with such a pattern. Ten of these tumors occurred on noncirrhotic livers. A signi®cant correlation was observed between the well dierentiated type of the tumor (grades I and II) and the abnormal nuclear staining (P50.01). None of the ®brolamellar carcinomas revealed any nuclear reactivity for b-catenin ( Figure  1d ).
Mutational analysis of b-catenin gene
Fourteen out of 73 HCC (19%) tested had point mutations or deletion in the b-catenin gene (Table 1) . Five interstitial deletions involving exon 3 have been characterized. The three largest deletions were directly detected on an agarose gel ( Figure 2 : 342723, K15, K41). The deleted segments on genomic DNA were ranging from 645 ± 1057 bp in size and involved the region extending from intron 2 to exon 4. The two remaining deletions (corresponding to the removal of 2 and 7 amino-acids) were detected on a sequencing gel (Table 1, K30 and 325699) . Regarding point mutations, missense mutations occurred in ®ve cases at serine residues which are likely to be implicated in the down regulation of b-catenin by the GSK-3b kinase (three at codon 33, one at codon 37 and one at codon 45) (representative sequences are shown in Figure 3 ). In the remaining samples, we identi®ed four missense mutations at neighboring sites, three at codons 32 (aspartic acid) and one at codon 34 (glycine).
b-catenin gene alterations were present in HCC arising in both cirrhotic (23%) and non-cirrhotic (17%) livers without signi®cant dierences. All deletions but one were present in HCC arising on non-cirrhotic livers (Table 1) . A signi®cant correlation between b-catenin gene alteration and nuclear accumulation of the protein was observed (P50.001). Among the 18 HCCs showing nuclear expression by immunohistochemistry, ten exhibited mutations or deletions of the b-catenin gene (Table  1 ). Abnormal nuclear staining or b-catenin mutations were not correlated to the etiological factors of HCC. However, b-catenin mutations have been detected in melanoma cell lines (Rubinfeld et al., 1997) and in a small proportion of sporadic colorectal (4%) (Morin et al., 1997; MuÈ ller et al., 1998) , prostate (5%) (Voeller et al., 1998) and endometrial (13%) (Fukuchi et al., 1998) carcinomas carrying the wild-type APC gene. These observations suggest that b-catenin mutation may substitute for APC gene inactivation in carcinogenesis. Recently, mutations in the b-catenin gene have been reported in hepatocellular carcinoma De la Coste et al., 1998) , however whether these alterations may be associated with speci®c clinico-pathological status or inappropriate protein expression has not yet been investigated.
In the present study, we have detected activating mutations in the human b-catenin gene in 14 of 73 liver tumors (19%), an incidence which conforms to what was previously described in HCC De la Coste et al., 1998) . Beside the ®ve point mutations involving the phosphorylation sites of exon 3 (serines 33, 37 and 45), we found four missense substitutions at neighboring sites at codons 32 and 34, anking the serine at codon 33. Such mutations aecting amino-acids immediately¯anking the glycogen-synthase-kinase 3b (GSK-3b) phosphorylation sites have been described in prostate and colorectal carcinomas (Voeller et al., 1998; Sparks et al., 1998) . They are also frequent in HCC as they represent 45% (9/20) of the mutations characterized so far in this type of neoplasia De la Coste et al., 1998) . It has been suggested that alterations at codons 32 and 34 may aect the ubiquitin-dependent proteolysis of b-catenin. In addition to these point mutations, we observed in our series a fairly high proportion of interstitial deletions of exon 3 (5 cases), particularly in HCCs arising on non-cirrhotic livers. Interestingly, such alterations have not only been characterized in colorectal carcinomas but also in mouse liver tumors and in a human hepatoblastoma cell line (HepG2) (De la Coste et al., 1998). The mechanism reponsible for these deletions is still unknown. The excess of deletions observed in our series (5/14, 36%) compared to the two previous reports (3/30, 15%) ; De la Coste et al., 1998) may be due, in part, to the speci®c characteristics of the population analysed.
To determine whether b-catenin mutations correlate with a nuclear accumulation of the protein, expression of b-catenin was analysed immunohistochemically in the 73 HCCs. In 18 cases, a prominent nuclear and cytoplasmic expression was observed. An association with genetic alterations of the b-catenin gene was found for ten of them, demonstrating a clear correlation between increased b-catenin stability and mutation. The inability of APC to down-regulate mutated b-catenin protein is likely to be responsible for its stabilization and inappropriate distribution. In the remaining eight cases, we did not ®nd any bcatenin gene alterations even though the intracellular concentration of the protein was signi®cantly elevated. Since our DNA analysis was restricted to exon 3, it is possible that genetic alterations outside of this exon may be responsible for this increase. Alternatively mutations in the APC gene may similarly have led to an accumulation of wild-type b-catenin protein as it has been reported in colorectal tumors (Inomata et al., 1996) or in sporadic aggressive ®bromatosis (Alman et al., 1997) . However this latter possibility seems improbable as rare genetic alterations have been detected in the APC locus in HCCs (Piao et al., 1997) . Furthermore, no LOH at this locus was observed in our eight tumors (data not shown). Finally, it is possible that other members of the Wnt signal-transduction pathway may be involved. In contrast to these eight cases showing an abnormal distribution of b-catenin in the absence of detectable mutations in exon 3, immunohistochemistry failed to detect nuclear accumulation of mutated b-catenin in four cases suggesting that other mechanisms, in addition to protein stabilization, may account for the oncogenic activation of b-catenin. Whereas nuclear expression of p53 protein is often correlated to poorly dierentiated HCC, nuclear accumulation of b-catenin was found to be signi®cantly correlated to well dierentiated tumors. The nuclear accumulation of bcatenin has also been observed in few cases of human liver adenomas (data not shown). This immunohistochemical pattern of b-catenin may support the early involvement of this protein in hepatocarcinogenesis.
The great majority of human HCCs occur on a cirrhotic liver. The reason for the relative excess of non-cirrhotic patients in our study population is due to the fact that tissues were obtained from surgical resections. The carcinogenesis of HCC in non-cirrhotic liver remains unclear. Except rare cases of genomic integration of hepatitis B virus which may play a direct role in tumor formation (Dejean et al., 1987; Wang et al., 1990) , no etiologic factors are usually found in these HCCs, in contrast to those arising on cirrhosis. In our series, if one excludes HCC of ®brolamellar type, a similar percentage of b-catenin gene alterations were observed between cirrhotic and non-cirrhotic groups (23 and 26% respectively). However the type of genetic alterations seems to be dierent with a higher incidence of interstitial deletions in the noncirrhotic group and missense substitutions in the cirrhotic group. It is still unknown whether these distinct mechanisms of activating mutations may be in¯uenced by exposure factors such as viruses. HCCs from regions of the world where the exposition to a¯atoxin B1 is common have not yet been studied. It would be interesting to compare the already published data with the molecular epidemiology of tumors coming from South-East Asia or African patients as it has been done for the p53 tumor suppressor gene product (Greenblatt et al., 1994) . Such studies may lead to the identi®cation of unraveled carcinogenic exposure associated with speci®c types of mutations. Interestingly, some reports have mentioned APC gene mutations in sporadic hepatoblastomas and in one case of ®brolamellar HCC associated with Gardner syndrome (Oda et al., 1996; Gruner et al., 1998) .
Moreover, a high frequency (48%) of b-catenin mutations has been recently reported in hepatoblastomas (Koch et al., 1999) . All these tumors occur in children or young adults and are developed on normal liver. Taken together, these data suggest that the Wnt/ APC/b-catenin pathway is important in HCC arising both in cirrhotic and non-cirrhotic livers.
In conclusion, activation mutations of b-catenin are frequent events in hepatocellular carcinoma with or without cirrhosis. In most cases, we have been able to correlate the genetic alterations consisting of both missense mutations in exon 3 and interstitial deletions involving exons 3 and 4 to a nuclear accumulation of the protein. However accumulating b-catenin could be detected in additional HCC cases in the absence of mutations in exon 3. Thus the use of immunohistochemistry combined with mutational analysis should allow a more complete assessment of the actual prevalence of b-catenin abnormalities in HCC and thus lead to a better understanding of the role of the Wnt developmental signaling pathway in liver carcinogensis.
Materials and methods
Patients
We retrieved 73 cases of HCC in 73 patients from the surgical ®le at our laboratory. Twenty-six HCCs had developed on an underlying cirrhosis (seven and six chronic viral hepatitis B and C respectively, seven alcoholic liver disease, four haemochromatosis and two of unknown etiology) and 47 cases on non-cirrhotic livers (seven and one chronic viral hepatitis B and C respectively and 39 of unknown etiology). According to the classi®cation of ®brosis by Ishak et al. (1995) , none of the 47 non-tumorous liver tissues from this last group excessed the grade 1 (®brous expansion of some portal areas with or without short ®brous septa). Of the 73 patients with HCC, 53 were men and 20 were women. There were 63 (86%) Caucasian and 10 (14%) non-Caucasian patients. The mean age was signi®cantly greater in cirrhotic (62 years) than in the non-cirrhotic group (49.7 years) (P50.001).
Among the 47 HCCs arising on a non-cirrhotic liver, nine corresponded to homogeneous and characteristic fibrolamellar carcinomas. The tumor cell dierentiation of all other HCCs were classi®ed according to the criteria of Edmondson and Steiner (1954) : three were classi®ed as grade I (well dierentiated), 34 as grade II (moderately dierentiated), 25 as grade III (poorly dierentiated) and two as grade IV (undierentiated type).
Immunohistochemistry
Tissues were ®xed in 10% of neutral buered formalin, routinely processed and embedded in paran. A representative tissue section including both HCC and adjacent nontumorous liver tissues from each patient was subjected to immunohistological study. After a microwave pre-treatment of sections in citrate buer, immunohistochemistry was performed using a three-step immunoperoxidase technique (Terris et al., 1996) . Deparanized sections were incubated for 40 min with 1/25 diluted anti-b-catenin monoclonal antibody (Transduction Lab, Lexington, KY, USA). Intrahepatic bile ducts were used as internal positive controls. The immunostaining result were evaluated semi-quantitatively by comparing the immunostaining intensity of HCC cells with that of the adjacent non-tumorous hepatocytes. Cellular localization of stain was also noted. A nuclear expression was considered positive when more than 10% of nuclei strongly stained for b-catenin.
DNA sequencing of exon 3 of b-catenin
High-molecular weight DNA was isolated from frozen tumor tissues according to standard procedures. Reactions were performed in 25 ml of a mixture containing 16PCR buer (50 mM KCl, 10 mM Tris (pH 8.9) 0.1% Tween 20, 1.5 mM MgCl 2 , 200 mM dATP, dGTP, dTTP, 10 mM dCTP), 20 pmol of each primer, 1 unit of Taq polymerase (Life Technologies, Cergy-Pontoise, France) in a Techne Cyclogene thermal cycler (OSI, Saint-Quentin-en-Yvelines, France).
To screen microdeletions or point mutations, exon 3 of bcatenin was ampli®ed using the following primers: forward, 5'-atttgatggagttggacatggc-3'; reverse 5'-ccagctacttgttcttgagtgaagg-3' (Genset, Paris, France). Fifty ng of DNA were ampli®ed in each reaction with the following reaction conditions: 1 cycle of 958C for 3 min, 30 cycles of 948C for 30 s, 558C for 30 s, and 728C for 30 s and 1 cycle of 728C for 10 min. The 231-bp PCR products were directly sequenced with the T7 Sequenase v2.0 PCR product sequencing kit (Amersham, Cleveland, Ohio, USA) using [a-35 S]dATP and loaded on glycerol-resistant gels.
Detection and analysis of deletions
Deletions were detected using primers¯anking exon 2 and exon 6 of the b-catenin gene (forward: 5'-ggtatttgaagtataccatac-3'; reverse: 5'-gctttcttggttgccataagc-3') (Nollet et al., 1996; Kitaeva et al., 1997) . Two-hundred ng of genomic DNA were ampli®ed using the procedure described above except for the elongation step which was extended to 90 s. The PCR products were examined by electrophoresis on a 1% agarose gel, stained with ethidium bromide and visualised by UV illumination. DNA fragments smaller than the wild-type (1846 bp) were puri®ed with a Qiaex gel extraction kit (Qiagen SA, Courtabúuf, France), cloned in a pGem-T easy vector (Promega, Lyon, France) and sequenced using a standard dideoxy method.
